Baidu
map

Arthritis Rheumatol:新发药物初治SLE患者无症状心肌损害的早期检测

2018-08-06 xiangting MedSci原创

这项研究首次表明即使在非活动性亚组中,药物初治的新发SLE也可能有无症状性心脏损害。

心脏磁共振(CMR)成像可以对系统性红斑狼疮(SLE)患者进行从组织特征到功能改变的心肌评估。然而,超声心动图可以表明何时存在心脏失代偿。使用CMR探索早期预警信号以筛查无症状性心脏受累对于确定治疗时机非常重要。

研究人员进行了临床评估和CMR研究。这是一项三中心前瞻性研究,纳入了50例药物初治的新发SLE患者、60例长期SLE患者和50例健康对照。在新发病组进行心肌酶、区域心肌纤维化指数-晚期钆增强存在和尺寸、应变变化和不能表明心脏受损的双室射血分数分析。新发病组的心肌native T1和细胞外容积(ECV,细胞外基质指数)升高(native T1为1369±79ms vs.1092±57ms对照组; ECV为32±5%vs. 24±3%对照组,p<0.001)。升高与SLE活动性无关。

这项研究首次表明即使在非活动性亚组中,药物初治的新发SLE也可能有无症状性心脏损害。心肌结构和功能的变化与SLE分期有关;这一发现表明早期检测心肌受累的价值。在肉眼纤维化和功能失代偿之前,心肌native T1值和ECV可作为心肌损伤的早期检测标志物,而不是目前的临床风湿和心脏指标。

原始出处:

本文系梅斯医学(MedSci)原创译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972515, encodeId=c10b19e25155e, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 29 02:11:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746461, encodeId=f6291e4646123, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Thu Aug 09 07:11:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344996, encodeId=035c134499673, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356878, encodeId=5b1113568e89b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485011, encodeId=6fd614850112a, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972515, encodeId=c10b19e25155e, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 29 02:11:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746461, encodeId=f6291e4646123, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Thu Aug 09 07:11:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344996, encodeId=035c134499673, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356878, encodeId=5b1113568e89b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485011, encodeId=6fd614850112a, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1972515, encodeId=c10b19e25155e, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 29 02:11:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746461, encodeId=f6291e4646123, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Thu Aug 09 07:11:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344996, encodeId=035c134499673, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356878, encodeId=5b1113568e89b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485011, encodeId=6fd614850112a, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1972515, encodeId=c10b19e25155e, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 29 02:11:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746461, encodeId=f6291e4646123, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Thu Aug 09 07:11:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344996, encodeId=035c134499673, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356878, encodeId=5b1113568e89b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485011, encodeId=6fd614850112a, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-08 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1972515, encodeId=c10b19e25155e, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 29 02:11:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746461, encodeId=f6291e4646123, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Thu Aug 09 07:11:00 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344996, encodeId=035c134499673, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356878, encodeId=5b1113568e89b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485011, encodeId=6fd614850112a, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Aug 08 07:11:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]

相关资讯

Arthritis Rheumatol:新诊断的系统性红斑狼疮患者有何表现?

在这个多中心队列中,确定了可以帮助区别早期SLE和类似疾病的临床表现。

礼来JAK抑制剂Olumiant治疗系统性红斑狼疮的2期临床试验获得成功

国际顶尖杂志Lancet发布了医药巨头礼来(Lilly)的一项临床II期试验的全部结果,该结果显示出其开发的JAK抑制剂Olumiant对全球系统性红斑狼疮(SLE)具有治疗益处。

Ann Rheum Dis:高敏肌钙蛋白与SLE炎性心血管受累的亚临床成像生物标记相关

SLE患者亚临床心肌损伤的患病率高,高敏肌钙蛋白水平升高证明了这一点。

Lancet:Baricitinib:治疗系统性红斑狼疮的潜在新药

系统性红斑狼疮(SLE)是一种慢性多系统自身免疫性疾病,其发病机制涉及许多依赖于Janus激酶(JAK)的细胞因子,因为JAK家族的细胞质蛋白酪氨酸激酶的,调节促炎细胞因子的信号传导,如1型干扰素、白细胞介素(IL6,12,23)等。

J Rheumatol:早发性系统性红斑狼疮的全外显子组测序

1例患者中发现了一种在SLE发病机制中起重要作用的新基因。研究人员建议在早发性和/或家族性SLE中寻找单基因病因/关联。

J Rheumatol:系统性红斑狼疮或血管炎使用环磷酰胺治疗后的带状疱疹

静脉注射CYC的系统性血管炎和SLE患者中带状疱疹的发病率高。

Baidu
map
Baidu
map
Baidu
map